deciphering the role of insulin-like growth factor-i receptor in trastuzumab resistance破译胰岛素样生长因子受体在曲妥珠单抗耐药的作用.pdfVIP

下载本文档

3
0
约5.99万字
约 8页
2017-08-27 发布于上海
举报
版权申诉

deciphering the role of insulin-like growth factor-i receptor in trastuzumab resistance破译胰岛素样生长因子受体在曲妥珠单抗耐药的作用.pdf

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

deciphering the role of insulin-like growth factor-i receptor in trastuzumab resistance破译胰岛素样生长因子受体在曲妥珠单抗耐药的作用

Hindawi Publishing Corporation Chemotherapy Research and Practice Volume 2012, Article ID 648965, 7 pages doi:10.1155/2012/648965 Review Article Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab Resistance Rita Nahta Departments of Pharmacology, Hematology and Medical Oncology, School of Medicine; Winship Cancer Institute; Molecular and Systems Pharmacology Program, Graduate Division of Biological and Biomedical Sciences, Emory University, Suite 5001, 1510 Clifton Road, Atlanta, GA 30322, USA Correspondence should be addressed to Rita Nahta, rnahta@ Received 25 April 2012; Accepted 19 June 2012 Academic Editor: Sue S. Yom Copyright © 2012 Rita Nahta. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Resistance to the HER2-targeted antibody trastuzumab is a major clinical concern in the treatment of HER2-overexpressing metastatic breast cancer. Increased expression or signaling of the insulin-like growth factor-I receptor (IGF-IR) has been reported in a subset of cell lines and clinical samples derived from trastuzumab-resistant breast cancers. Genetic and pharmacologic ¨ inhibition of IGF-IR signaling has been shown to improve response to trastuzumab in trastuzumab-naıve and trastuzumab- resistant models. In this paper, we will discuss the role of IGF-IR signaling in trastuzumab resistance. Further, we will discuss cotargeting IGF-IR and HER2 as a potential therapeutic strategy for HER2-over-expressing breast cancers that have